Please login to the form below

Not currently logged in
Email:
Password:

CureVac

This page shows the latest CureVac news and features for those working in and with pharma, biotech and healthcare.

Boehringer bolts on another immuno-oncology company

Boehringer bolts on another immuno-oncology company

Immunotherapeutics and earlier alliances with Siamab, AbeXXa Biologics, CureVac and Philogen.

Latest news

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    805. Curevac / Boehringer Ingelheim. Licence and collaboration. Messenger RNA vaccine (CV9202) in combination with afatininib and chemo-radiation for lung cancer.

  • Pharma deals during September 2014 Pharma deals during September 2014

    Boehringer Ingelheim has taken a licence to Curevac's messenger RNA vaccine for one of its compounds and the Californian company, Sutro, has signed an early stage deal with Merck KGaA

  • Pharma deals during July 2014 Pharma deals during July 2014

    Scandinavia. CureVac's relationship with Sanofi Pasteur dates back to 2011 when the companies entered into a collaboration and option agreement covering mRNA-based vaccines generated using CureVac's RNActive technology ... CureVac is also eligible to

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    225. CureVac/ Sanofi Pasteur. Exercise of option, licence. RNActive vaccine technology vs undisclosed pathogens (preclinical).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • CureVac’s CEO appointed to EC High Level Group CureVac’s CEO appointed to EC High Level Group

    CureVac’ s CEO appointed to EC High Level Group. Dr Ingmar Hoerr will advise on Horizon 2020 and future innovation programmes. ... Dr Ingmar Hoerr, chief executive officer of clinical-stage mRNA technology specialist CureVac, has been appointed to the

  • CureVac appoints chief financial officer CureVac appoints chief financial officer

    CureVac appoints chief financial officer. Pierre Kemula joins the mRNA company’ s management board. ... Tübingen, Germany-based mRNA firm CureVac has appointed Pierre Kemula as its new chief financial officer.

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics